NCT05496725View on ClinicalTrials.gov

Evaluate Bioequivalence of Micafungin (50mg/Vial)

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 6, 2022

Primary Completion Date

May 30, 2022

Study Completion Date

July 28, 2022

Conditions
Invasive Candidiasis
Interventions
DRUG

Micafungin

Pharmacokinetic study under fasting conditions

Trial Locations (1)

Unknown

Taichung Veterans General Hospital, Taichung

All Listed Sponsors
lead

Yung Shin Pharm. Ind. Co., Ltd.

INDUSTRY

NCT05496725 - Evaluate Bioequivalence of Micafungin (50mg/Vial) | Biotech Hunter | Biotech Hunter